Myelofibrosis is an inflammation-driven systemic disease in which cytokines, fibrosis and clonal evolution are inextricably linked. New data show that the control of inflammation has a decisive influence on the course of the disease. Modern therapies that simultaneously modulate JAK signaling pathways, hepcidin regulation and inflammatory networks mark a real paradigm shift.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Myelofibrosis
New findings on the role of inflammation in pathogenesis
- Incretin mimetics for obesity and prediabetes
Liraglutide, semaglutide and tirzepatide: considerable evidence base
- Treatment of infected wounds and wounds at risk of infection
Focus on an interdisciplinary perspective
- Chronic and hard-to-heal wounds
Benefit from the advantages of outpatient negative pressure wound therapy
- COPD
Even a single moderate exacerbation can be a predictor of mortality
- HER2+ metastatic breast cancer
New therapeutic standards with SHR-A 1811
- Angina tonsillaris: clinical management
Conservative therapy or surgery?
- Dermocosmetic for mild to moderate acne